Incannex wins approval of overseas findings, secures A$5.1 million R&D tax refund
Reuters2026/08/11 11:32- Incannex received A$ 5.1 million from Australia’s R&D Tax Incentive Program following approval of overseas findings for FY25.
- Total 2026 proceeds under the program reached more than A$ 11.2 million in non-dilutive funding.
- Cash inflow supports clinical development programs, including IHL-42X and PSX-001.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260

10-Yr Benchmark Govt Yields - Germany vs Other Nations